Alpha Thalassemia Market Emerging as a High-Growth Healthcare Investment Space Through 2036 - DelveInsight

DelveInsight's "Alpha Thalassemia Market Insights, Epidemiology, and Market Forecast-2036′′ report offers an in-depth understanding of the Alpha Thalassemia, historical and forecasted epidemiology as well as the Alpha Thalassemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Alpha Thalassemia, offering comprehensive insights into the Alpha Thalassemia revenue trends, prevalence, and treatment landscape. The report delves into key Alpha Thalassemia statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Alpha Thalassemia therapies. Additionally, we cover the landscape of Alpha Thalassemia clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Alpha Thalassemia treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Alpha Thalassemia space.

Get a Free sample for the Alpha Thalassemia Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/alpha-thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Some of the key facts of the Alpha Thalassemia Market Report:
• The Alpha Thalassemia market size was valued ~USD 150 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2022-2036).
• In December 2025, Agios Pharmaceuticals (AGIO) announced that the FDA has not yet issued a decision on the company's supplemental new drug application (sNDA) for its marketed therapy, Pyrukynd (mitapivat), for thalassemia. The application seeks approval to expand Pyrukynd's use to adult patients with both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.
• In December 2025, Genetix Biotherapeutics Inc. announced its selection to participate in the American Society of Hematology's (ASH) exclusive press program ahead of the 67th ASH Annual Meeting, scheduled in Orlando, Florida, from December 6-9, 2025. The company's abstract, "Accelerating access to gene therapy: Lessons from commercial implementation in sickle cell disease and transfusion-dependent thalassemia," was chosen by the ASH Program Committee as one of the most impactful datasets submitted this year.
• In June 2025, Agios Pharmaceuticals presented new data on the company's PK activators, mitapivat and tebapivat, will be featured in oral and poster presentations during the 30th EHA Congress 2025.
• In January 2025, Agios Pharmaceuticals (AGIO) announced that the FDA has accepted its supplemental new drug application (sNDA) for label expansion of Pyrukynd, its only marketed drug, for the treatment of thalassemia.
• Key Alpha Thalassemia Companies: Forma Therapeutics, Inc., Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharmaceuticals, and others
• Key Alpha Thalassemia Therapies: Etavopivat tablets, GMCN-508A, Luspatercept, Mitapivat, and others
• About 300 million people around the world have the "thalassemia trait", which puts them at risk of having children with some form of thalassemia. More than 1 million people have non-transfusion-dependent thalassemia, while more than 100,000 people have transfusion-dependent thalassemia. In the US, there are at least 1,200 people with transfusion-dependent thalassemia.
• Worldwide, at least 300,000 children are born each year affected with a severe form of hemoglobinopathy. Furthermore, at least 20% of the global population carries at least a single gene deletion for alpha thalassemia.
• Roughly 56,000 children are born annually with severe alpha or beta thalassemia, of whom more than half require regular transfusions, and 5500 die perinatally due to alpha thalassemia major (hydrops fetalis).
• Over half of alpha-thalassemia cases in Japan are of Southeast Asian origin, while the rest involve unique, largely undetermined Japanese mutations, indicating a dual origin. Beta-thalassemia occurs in about 1 in 600-1,000 people, and alpha(+)-thalassemia (-a/) in about 1 in 400, making alpha-thal trait (-a/-a) extremely rare.

Alpha Thalassemia Overview
Alpha thalassemia is a genetic blood disorder caused by mutations in the genes responsible for producing alpha-globin, a component of hemoglobin. Hemoglobin is essential for carrying oxygen throughout the body, and a deficiency in alpha-globin leads to abnormal red blood cells and reduced oxygen transport. The condition ranges in severity, from silent carriers with no symptoms to severe forms like Hemoglobin H disease and alpha thalassemia major, which can cause life-threatening anemia. Common symptoms include fatigue, pale skin, and growth delays. Treatment depends on severity and may include blood transfusions, iron chelation therapy, or bone marrow transplantation.

To Know in detail about the Alpha Thalassemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Alpha Thalassemia Market Forecast
https://www.delveinsight.com/sample-request/alpha-thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Alpha Thalassemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Alpha Thalassemia Epidemiology Segmentation:
The Alpha Thalassemia market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:
• Total Diagnosed Prevalent Cases of Thalassemia
• Total Diagnosed Prevalent Cases of Alpha-thalassemia
• Total Diagnosed Prevalent Cases of Alpha-thalassemia based on Transfusion Requirement
• Total Treatable Cases of Alpha-thalassemia

Download the report to understand which factors are driving Alpha Thalassemia epidemiology trends @ Alpha Thalassemia Epidemiology Forecast
https://www.delveinsight.com/sample-request/alpha-thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Alpha Thalassemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Alpha Thalassemia market or expected to get launched during the study period. The analysis covers Alpha Thalassemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Alpha Thalassemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Alpha Thalassemia Therapies and Key Companies
• PYRUKYND (mitapivat): Agios Pharmaceuticals
• Etavopivat tablets: Forma Therapeutics, Inc.
• GMCN-508A: Genmedicn Biopharma Ltd.
• Luspatercept: Bristol-Myers Squibb
• Mitapivat: Agios Pharmaceuticals

Discover more about therapies set to grab major Alpha Thalassemia market share @ Alpha Thalassemia Treatment Landscape
https://www.delveinsight.com/sample-request/alpha-thalassemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gaurav

Alpha Thalassemia Market Drivers
• Increasing Prevalence genetic disorders and advancement in healthcare technologies, growing demand for treatment for Alpha Thalassemia are some of the important factors that are fueling the Alpha Thalassemia Market.

Alpha Thalassemia Market Barriers
• However, lack of available appropriate treatments and procedures, high cost of treatment and other factors are creating obstacles in the Alpha Thalassemia Market growth.

Scope of the Alpha Thalassemia Market Report
• Study Period: 2022-2036
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Alpha Thalassemia Companies: Forma Therapeutics, Inc., Genmedicn Biopharma Ltd., Bristol-Myers Squibb, Agios Pharmaceuticals, and others
• Key Alpha Thalassemia Therapies: Etavopivat tablets, GMCN-508A, Luspatercept, Mitapivat, and others
• Alpha Thalassemia Therapeutic Assessment: Alpha Thalassemia current marketed and Alpha Thalassemia emerging therapies
• Alpha Thalassemia Market Dynamics: Alpha Thalassemia market drivers and Alpha Thalassemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Alpha Thalassemia Unmet Needs, KOL's views, Analyst's views, Alpha Thalassemia Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.